This is a non-core endpoint: only basic statistics are computed.
See its core counterpart C3_SALIVARYNAS_EXALLC for full statistics.
Malignant neoplasm of other and unspecified major salivary glands
C3_SALIVARYNAS
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
109 |
4. Check minimum number of eventsNone |
109 |
5. Include endpointsNone |
109 |
6. Filter based on genotype QC (FinnGen only) |
109 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF9
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of other and unspecified major salivary glands
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of other and unspecified major salivary glands, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm of head and neck
- Malignant neoplasm of head and neck, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm
- Any event in cancer register
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 109 | 53 | 56 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | 65.01 | 64.42 | 65.57 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 101
- Matched controls
- 1008
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
ELB30
NOMESCO Finland
Excision of submandibular gland
+∞
46.5
41
*
C08.09
ICD-10 Finland
Malignant tumor of the submandibular or submaxillary gland, other or unspecified histology
+∞
34.3
31
*
D11.70
ICD-10 Finland
Gland sublingual
+∞
33.1
30
*
PJD81
NOMESCO Finland
Excision of lymph nodes from upper part of neck
293.7
23.7
23
*
EP1AE
NOMESCO Finland
Neck ultrasound examination
28.6
23.6
32
16
R22.1
ICD-10 Finland
Localized swelling, mass and lump, neck
32.1
23.0
30
13
PJD71
NOMESCO Finland
Extended sparing excision of cervical lymph nodes
+∞
21.6
20
*
C08.02
ICD-10 Finland
Cystic adenocarcinoma of the submandibular or submaxillary glands
+∞
21.6
20
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
24.5
21.2
30
17
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
7.9
20.6
69
216
8200/3-C08.0
ICD-O-3
Adenoid cystic carcinoma of submandibular gland
+∞
19.4
18
*
C08.00
ICD-10 Finland
Malignant tumor of submandibular or submaxillary gland, not histology
+∞
16.0
15
*
R59.0
ICD-10 Finland
Localized enlarged lymph nodes
94.1
15.0
16
*
D37.00
ICD-10 Finland
Aryepiglottic fold marginal zone
+∞
14.9
14
*
XX3DW
NOMESCO Finland
Time consuming IT work
8.9
14.6
33
52
D11.0
ICD-10 Finland
Benign neoplasm: Parotid gland
35.9
14.4
18
6
EP1CG
NOMESCO Finland
Extensive MRI examination of soft tissue of neck with high intesity magnet
40.3
14.0
17
5
EP1DG
NOMESCO Finland
Very extensive examination of soft tissue of neck with high intesity magnet
147.4
12.7
13
*
130
Kela drug reimbursment
Malignant tumour
7.6
12.1
30
53
YA1BD
NOMESCO Finland
Extensive CT examination of head and neck for dose design of radiotherapy
73.7
11.9
13
*
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
12.7
10.8
19
18
C08.90
ICD-10 Finland
Malignant tumor in unspecified large salivary gland without histology
+∞
10.6
10
*
PJD41
NOMESCO Finland
Excision of cervical lymph nodes
33.6
9.6
12
*
C83.80
ICD-10 Finland
B-cell lymphoma in marginal zone
109.8
9.6
10
*
C08.0
ICD-10 Finland
Malignant neoplasm: Submandibular gland
+∞
9.5
9
*
C08.01
ICD-10 Finland
Diverse adenocarcinoma of the mandibular salivary gland
+∞
9.5
9
*
SAA03
NOMESCO Finland
Extended examination of mouth
3.7
9.2
57
259
A07AA02
ATC
nystatin; oral
8.4
8.8
19
27
K08.1
ICD-10 Finland
Loss of teeth due to accident, extraction or local periodontal disease
6.1
8.6
24
49
C77.0
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Lymph nodes of head, face and neck
97.8
8.5
9
*
N02AA05
ATC
oxycodone; systemic
4.6
8.5
32
92
9699/3-C08.0
ICD-O-3
Marginal zone B-cell lymphoma, NOS, of submandibular gland
+∞
8.4
8
*
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
19.2
8.3
12
7
WF049
NOMESCO Finland
Radiotherapy of metastasis
14.7
8.1
13
10
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
3.3
7.8
57
282
JN4KR
NOMESCO Finland
Whole body very extensive metabolic PET with CT
48.9
7.8
9
*
XW000
NOMESCO Finland
Bone marrow biopsy
13.3
7.8
13
11
Z51.5
ICD-10 Finland
Palliative care
6.8
7.7
19
33
8430/3-C08.0
ICD-O-3
Mucoepidermoid carcinoma of submandibular gland
+∞
7.4
7
*
8200/3-C08.9
ICD-O-3
Adenoid cystic carcinoma of major salivary gland, NOS
+∞
7.4
7
*
YA1VG
NOMESCO Finland
MRI examination of head and neck with high intesity magnet for dose design of radiotherapy
+∞
7.4
7
*
EL4AT
NOMESCO Finland
Salivary gland cytology with ultrasound guidance
+∞
7.4
7
*
C08.94
ICD-10 Finland
Mucoepidermoid carcinoma of an unspecified large salivary gland
+∞
7.4
7
*
ZX090
NOMESCO Finland
Other technic of radiotherapy
13.4
7.3
12
10
YA1AD
NOMESCO Finland
CT examination of head and neck for dose design of radiotherapy
32.5
7.3
9
*
XW1AT
NOMESCO Finland
Biopsy from other organ close to skin with ultrasound quidance
43.0
6.9
8
*
JN6AD
NOMESCO Finland
CT of torso and neck
43.0
6.9
8
*
ZX070
NOMESCO Finland
Intensity modified radiotherapy
13.5
6.8
11
9
YA1CD
NOMESCO Finland
Very extensive CT examination of head and neck for dose design of radiotherapy
+∞
6.3
6
*
EJB30
NOMESCO Finland
Excision of lesion of floor of mouth
+∞
6.3
6
*
C08.9
ICD-10 Finland
Malignant neoplasm: Major salivary gland, unspecified
+∞
6.3
6
*
C08.91
ICD-10 Finland
Adenocarcinoma of mixed cell type in unspecified large salivary gland
+∞
6.3
6
*
EHB00
NOMESCO Finland
Excision of lesion of palate
+∞
6.3
6
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
8.9
6.0
12
15
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
26
16
21.03
31.65
1.5
1.3
—
—
—
0
0
63
423
2.16
3.75
3.9
4.3
—
—
—
0
0
23
104
2.54
3.46
11.4
8.1
—
—
—
0
0
7
10
7.39
3.42
1.7
1.1
—
—
—
0
0
50
322
2.02
3.18
3.7
3.5
2.4
2.3
mmol/l
0.76
44
274
6
9
6.98
2.90
2.0
2.2
14.4
12.4
ug/l
—
6
9
9
25
3.83
2.64
1.1
1.6
—
—
—
0
0
9
26
3.68
2.54
1.1
1.6
—
—
—
0
0
62
457
1.83
2.43
7.5
7.2
1.2
1.2
mmol/l
0.09
45
385
16
75
2.33
2.21
3.2
3.5
69.6
54.6
ml/min/173m2
—
5
30
7
19
3.86
2.19
1.1
1.6
—
—
—
0
0
6
14
4.47
2.18
1.2
1.5
—
—
—
0
0
7
20
3.67
2.09
1.1
1.5
—
—
—
0
0
6
15
4.17
2.07
1.2
1.6
—
—
—
0
0
56
416
1.71
2.02
6.1
6.3
1.2
1.2
mmol/l
0.97
46
373
6
17
3.67
1.86
1.7
1.3
—
—
—
0
0
12
54
2.37
1.81
1.2
1.3
—
—
—
0
0
84
717
1.75
1.64
12.0
7.8
82.1
77.4
u/l
0.30
75
668
6
20
3.11
1.60
1.2
1.3
—
—
—
0
0
5
15
3.44
1.54
1.2
1.7
—
—
—
0
0
31
211
1.66
1.48
2.0
2.4
—
—
—
0
0
5
17
3.03
1.37
1.2
1.5
—
—
—
0
0
23
151
1.66
1.25
1.9
1.8
—
—
—
0
0
5
21
2.44
1.10
1.0
1.3
—
—
—
0
0
10
53
1.98
1.05
1.3
1.6
—
—
—
0
0
0
32
0.00
0.97
0.0
2.8
—
0.0
—
0
32
17
111
1.63
0.94
1.2
1.7
—
—
—
0
0
11
178
0.58
0.93
1.2
1.2
0.4
0.8
u/ml
—
6
43
17
112
1.61
0.91
1.6
1.7
—
—
—
0
0
95
880
1.62
0.88
21.5
15.2
32.3
21.9
mg/l
1.65
79
699
6
31
1.99
0.86
2.0
1.9
—
—
—
0
0
15
98
1.62
0.84
1.2
1.4
—
—
—
0
0
0
24
0.00
0.80
0.0
1.8
—
—
—
0
0
98
921
1.63
0.77
23.3
17.6
139.3
139.6
mmol/l
0.64
93
892
77
693
1.38
0.76
4.5
4.4
12.6
13.3
mm/h
0.17
67
628
5
25
2.05
0.73
1.0
1.3
—
—
—
0
0
16
110
1.53
0.73
5.4
4.9
29.4
30.8
%
—
10
64
5
28
1.82
0.67
2.2
1.8
—
—
—
0
0
43
502
0.76
0.65
2.8
2.7
—
—
—
0
0
14
97
1.51
0.62
3.9
3.9
—
—
—
0
0
63
561
1.29
0.61
3.2
3.0
79.0
52.2
u/l
0.64
56
528
0
21
0.00
0.60
0.0
1.5
—
—
—
0
0
0
22
0.00
0.60
0.0
1.7
—
—
—
0
0
0
22
0.00
0.60
0.0
1.1
—
—
—
0
0
6
35
1.75
0.59
1.3
2.3
—
—
—
0
0
35
294
1.28
0.52
2.8
3.1
1073.1
1206.1
ng/l
0.11
29
247
40
461
0.79
0.52
4.9
4.0
0.0
0.0
estimate
0.00
13
87
98
937
1.45
0.50
14.1
11.1
24.2
24.9
u/l
0.21
89
898
7
50
1.43
0.46
5.1
3.4
38.9
47.9
%
—
7
50
31
362
0.80
0.44
3.7
4.8
1.8
2.9
ug/l
0.67
25
323
19
236
0.76
0.44
1.6
1.6
19.5
22.1
nmol/l
0.33
14
189
0
17
0.00
0.41
0.0
1.8
—
—
—
0
0
0
18
0.00
0.40
0.0
1.5
—
—
—
0
0
97
934
1.35
0.37
25.2
18.2
77.5
80.9
umol/l
0.87
97
934
41
456
0.84
0.34
5.3
5.5
0.0
0.0
estimate
0.00
13
92
41
367
1.19
0.33
5.3
3.9
84.6
31.6
ng/l
0.62
35
270
80
836
0.84
0.29
3.7
4.2
1.3
1.3
mmol/l
0.10
69
750
84
869
0.85
0.23
4.1
4.7
1.4
1.4
mmol/l
0.07
72
781
19
218
0.84
0.22
2.3
2.9
0.6
0.7
ug/l
1.62
13
148
0
11
0.00
0.21
0.0
4.6
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
48.8
—
0
6
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
2.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.8
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
38
349
1.14
0.21
3.5
3.2
—
—
—
0
0
0
13
0.00
0.21
0.0
2.9
—
—
—
0
0
42
451
0.89
0.20
4.7
4.0
0.0
0.0
estimate
0.00
12
91
6
79
0.75
0.16
2.5
2.2
437.0
361.4
nmol/l
—
6
70
7
86
0.80
0.15
1.9
2.9
28.4
27.9
u/l
—
7
73
87
891
0.88
0.15
4.6
5.3
2.8
2.7
mmol/l
0.49
75
801
26
238
1.12
0.15
5.6
4.3
0.0
0.0
estimate
0.00
12
87
69
668
1.09
0.12
3.9
4.0
14.6
15.1
pmol/l
0.79
58
592
37
391
0.92
0.11
2.0
2.0
98.1
94.5
pmol/l
0.11
15
189
5
48
1.04
0.09
2.2
3.2
0.3
0.1
e6/l
—
5
48
6
55
1.10
0.09
1.8
1.5
—
—
—
0
0
27
286
0.93
0.08
2.8
4.2
17.5
22.3
%
1.41
14
135
86
875
0.92
0.08
3.8
4.7
4.7
4.5
mmol/l
0.52
72
796
6
72
0.82
0.08
3.3
2.1
65.5
125.5
ng/l
—
6
62
86
846
1.08
0.07
21.0
14.5
78.2
77.5
ml/min/173m2
0.15
71
689
18
192
0.93
0.06
2.0
1.7
1372.5
1309.5
nmol/l
0.07
11
149
81
821
0.95
0.04
4.5
4.8
2.2
1.9
mu/l
0.92
69
734
11
119
0.92
0.04
1.5
1.4
—
—
—
0
0
21
201
1.06
0.03
1.7
1.8
576.4
498.4
pmol/l
0.33
16
166
21
217
0.96
0.01
2.4
2.1
3.1
2.7
mg/l
0.46
16
192
34
347
0.97
0.01
4.5
4.3
—
—
—
0
0
19
192
0.99
0.00
1.8
1.8
2.3
1.1
mg/l
0.50
13
148
16
163
0.98
0.00
1.3
1.8
29.9
29.8
s
0.01
16
156
84
841
0.99
0.00
5.9
6.3
40.2
40.7
mmol/mol
0.24
72
778
87
869
1.01
0.00
4.5
4.9
6.1
6.0
mmol/l
0.18
74
788
0
6
0.00
0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
0.00
0.0
3.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
5
52
0.96
0.00
16.2
6.5
25.1
25.0
mmol/l
—
5
52
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
3.0
—
—
—
0
0
0
9
0.00
0.00
0.0
4.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
4.8
—
60.7
—
0
5
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
2.5
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_SALIVARYNAS – Malignant neoplasm of other and unspecified major salivary glands
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).